By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Upsher-Smith Laboratories, Inc. 

14905 23rd Avenue North

Minneapolis  Minnesota  55447  U.S.A.
Phone: 800-328-3344 Fax:


Company News
Upsher-Smith Laboratories To Present New Data On Qudexy XR (topiramate) Extended-Release Capsules And USL261 (Investigational Intranasal Midazolam) 11/23/2015 7:28:48 AM
Upsher-Smith Laboratories Release: Data Published In Epilepsia Shows USL261 (Intranasal Midazolam) Demonstrated A Promising Pharmacokinetic Profile, Including Increased Relative Bioavailability, When Compared With Injectable Midazolam Administered Intranasally 11/9/2015 7:29:40 AM
Upsher-Smith Laboratories Names Rusty Field President 8/24/2015 7:53:59 AM
Upsher-Smith Laboratories Receives FDA Approval For Generic Version Of Namenda (Memantine HCl) Tablets 8/10/2015 8:03:12 AM
Upsher-Smith Laboratories's ANDROXY (Fluoxymesterone Tablets, USP) CIII Now Available 7/27/2015 11:24:47 AM
Upsher-Smith Laboratories Release: FDA Approves Expanded Indication For Qudexy XR (Topiramate) Extended-Release Capsules Within The Pediatric Population 6/1/2015 7:30:06 AM
Upsher-Smith Laboratories Research On Qudexy XR (topiramate) Extended-Release Capsules Highlighted At the 2015 American Academy of Neurology Annual Meeting 4/21/2015 11:34:31 AM
Upsher-Smith Laboratories To Present Data Evaluating The Long-Term Safety And Efficacy Of Qudexy XR (Topiramate) Extended-Release Capsules And Alternative Administration Techniques 4/13/2015 7:54:25 AM
Upsher-Smith Laboratories To Debut I Hate Seizures Campaign At Ninth Annual National Walk For Epilepsy 4/10/2015 10:50:23 AM
Upsher-Smith Laboratories Honors 45 Innovative Pharmacists From Across The Nation 2/24/2015 10:24:58 AM